European best practice guidelines 14-16: Inadequate response to epoetin

Nephrology Dialysis Transplantation

Volumn 15, Issue SUPPL. 4, 2000, Pages 43-50

  Horl, W H ^a   Jacobs, C ^a   Macdougall, I C ^a   Valderrabano, F ^a   Parrondo, I ^a   Thompson, K ^a   Carveth, B G ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; C REACTIVE PROTEIN; CARNITINE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FERRITIN; FOLIC ACID; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; VITAMIN D;

ADULT; ANEMIA; ARTICLE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG RESPONSE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HEMOGLOBINOPATHY; HEPATITIS; HUMAN; INFECTION; INFLAMMATION; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEOPLASM; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

EID: 0033809678     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.suppl_3.43     Document Type: Article

References (35)

1. Worsening of anaemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients
2. ACE-inhibitors do not decrease rHuEPO response in patients with end-stage renal failure
3. ACE-inhibitors do not affect erythropoietin efficacy in hemodialysis patients
4. Do ACE-inhibitors influence the dose of rHuEPO in dialysis patients?
5. Does captopril decrease the effect of human recombinant erythropoietin in hemodialysis patients?
6. Angiotensin converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients
7. Unresponsiveness to recombinant human erythropoietin in haemodialysis patients: Possible implications of angiotensin-converting enzyme inhibitors
8. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: Role of growth factors and cytokines
9. Mechanism of angiotensin converting enzyme inhibitor related anaemia in renal transplant recipients
10. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?
11. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients
12. Effects of angiotensin-converting enzyme inhibitors on anaemia and erythropoietin requirements in peritoneal dialysis patients
13. Higher erythropoietin requirement in peritoneal dialysis patients treated with angiotensin-converting enzyme inhibitors (ACEI)
14. Erythropoietin and iron
15. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
16. Is there a role for adjuvant therapy in patients being treated with epoetin?
17. The impact of withdrawing ACE-inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients
18. The role of ACE-inhibitors and angiotensin II receptor blockers in the response to epoetin
19. Effect of angiotensin-converting enzyme inhibitors on response to erythropoetin therapy in chronic dialysis patients
20. The response to recombinant human erythropoietin in patients with the anemia of end stage renal disease is correlated with serum carnitine levels
21. Low dose of L-carnitine impairs membrane fragility of erythrocytes in hemodialysis patients
22. Effects of low doses of L-carnitine on the response to recombinant human erythropoietin in hemodialyzed children: About two cases
23. L-Carnitine effects on anemia in hemodialyzed patients treated with erythropoietin
24. Response to recombinant erythropoietin (r-HuEPO) and L-carnitine combination in patients with anaemia of end stage renal disease
25. L-Carnitine and erythropoietin requirements in hemodialysis patients
26. 3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients
27. Medical treatment of severe hyperparathyroidism and its influence on anaemia in end-stage renal failure
28. High dose alfacalcidol improves anemia in patients on haemodialysis
29. Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients
30. Intravenous calcitriol improves anemia and reduces the need for erythropoietin in hemodialysis patients
31. Resistance to erythropoietin in iron overloaded haemodialysis patients can be overcome by ascorbic acid administration
32. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload
33. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload
34. Intravenous ascorbic as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia
35. Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy